Zobrazeno 1 - 1
of 1
pro vyhledávání: '"E. Weisbarth-Riedel"'
Autor:
Anthony Sebba, Kimme L. Hyrich, N. Schlesinger, Juan J. Scali, Andrea Rubbert-Roth, A. Pikhlak, R. Cartwright, Deborah P M Symmons, E. Weisbarth-Riedel, K Chakravarty, B. Bodalia, E. Incera, I. Kone-Paut, Darren M. Ashcroft, A. E. Yücel, Sarah Mapplebeck, R. Preiss, Katalin Dankó, David A. Isenberg, Patrick Gordon, Alexander So, M. Gattorno, Moetaza M. Soliman, John B Winer, U. Arulmani, Bryan Lecky, V. Murphy, G. Krammer, P. Quartier, K. Leslie, E. Ramos, E. Hachulla, Kath D. Watson, F. Zulian, Ernest Choy, George D. Kitas, Dimitrios Christidis, David Scott, I. Foeldvari, Bhaskar Dasgupta, Mark Lunt, Ronald F van Vollenhoven, D. Richard, Beverley White-Alao, J. Hoyer, M. De Meulemeester, H. J. Lachmann, L. Lepore, J. Kerrane, P. N. Hawkins, Nada Hassan, Emma Vernon, Anna Kowalczyk, Fowzia Ibrahim, Moshe Zilberstein, Robert G. Cooper, Alan Hakim, Mark C. Genovese, P. Sallstig, Bridget Griffiths, J. B. Kuemmerle-Deschner
Background: Rituximab (RTX) in combination with methotrexate (MTX) has been licensed since 2006 for the management of severe active rheumatoid arthritis (RA) in patients who have failed at least one anti-tumour necrosis factor (anti-TNF) therapy. Pub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f3c5b182b2ef00bc565dc0e13bf4cf7
http://doc.rero.ch/record/300341/files/ker073.pdf
http://doc.rero.ch/record/300341/files/ker073.pdf
